Autoimmune diabetes shows extreme variation in age of onset and clinical presentation, although most studies have been done in children with the most severe subtype. Disease risk is strongly associated with HLA-DRB1*0301-DQA1*0501-DQB1*0201 (DR3-DQ2), but it has not been possible to separate the effects of the DR and DQ alleles. We have identified a large Bedouin kindred in which a high prevalence of islet autoimmunity is associated with two different DR3 haplotypes, one carrying the usual DQ2 and the other carrying DQA1*0102-DQB1*0502 (DQ5). Results of prospective follow-up studies indicate that DR3 is associated with the initial activation of islet autoimmunity whereas DQ2 is associated with early-onset and severe clinical disease. The association signals map to a 350-kb interval, thus implicating primary effects for DR3 and DQ2. Overall, our results emphasize the importance of prospective genetic studies that examine the full range of variation in the initiation, progression and expression of autoimmune disease.
Introduction
Autoimmune diabetes is caused by T-cell-mediated destruction of insulin-producing b-cells in pancreatic islets, eventually resulting in absolute dependence on insulin for survival. Disease onset is typically preceded by a prodromic phase characterized by islet infiltration by immuno-inflammatory cells (insulitis) and circulating autoantibodies to insulin, glutamic acid decarboxylase (GAD65), protein tyrosine phosphatase IA-2 (IA-2/ ICA512) and, less frequently, other autoantigens. [1] [2] [3] The presence of autoantibodies in unaffected individuals and in patients initially misclassified as type 2 (non-autoimmune) diabetes identifies those at highest risk for progressing to insulin-dependent diabetes. [4] [5] [6] However, the length of the preclinical stage is highly variable, and fluctuations in autoantibody titers and expression are common. 7 Historically considered a disease of childhood, it is now clear that autoimmune diabetes may occur at any age, and, indeed, the majority of patients may develop the disease as adults. Nevertheless, most of what is known about the genetics of autoimmune diabetes is derived from studies of patients who developed the disease as children.
Like nearly all autoimmune diseases, autoimmune diabetes is associated with variation in the major histocompatibility complex (MHC) at chromosome 6p21. Many studies have confirmed the predisposing effects of two HLA class II haplotypes, DRB1*04-DQA1*0301-DQB1*0302 (DR4-DQ8) and DRB1*0301-DQA1*0501-DQB1*0201 (DR3-DQ2), and the protective effects of another class II haplotype, DRB1*15-DQA1*0102-DQB1*0602 (DR2). 8, 9 Similar HLA disease associations are seen in both children and adults, but the synergistic effects of heterozygosity for the two highest risk haplotypes 8 and the dominant protective effects of the lowest risk haplotype are most apparent in the young. 10, 11 Far less is known about HLA effects on the emergence of autoantibodies, and it is controversial whether HLA influences the initial activation of islet autoimmunity, the severity and age of onset of clinical disease or both. 7, 12, 13 A direct involvement of class II molecules in disease pathogenesis has been implicated by their functional role in binding and presenting peptides to T lymphocytes, and studies showing differences in antigen selectivity and binding affinity for the products of high-and low-risk alleles. [14] [15] [16] [17] However, there is limited genetic evidence to support this view because of the strong linkage disequilibrium across the MHC. 16, 18, 19 DR3-DQ2 is of special interest, in part because of its association with multiple immunopathologies and in part because of the extended conservation of this haplotype. 20 Unlike DR4 and DQ8, which occur on several DR-DQ haplotypes, DR3 occurs almost exclusively on haplotypes also carrying DQ2, and conversely, DQ2 occurs almost exclusively on haplotypes also carrying DR3. 21 Indeed, one third or more of DR3-DQ2 haplotypes display sequence conservation extending 4-6 Mb telomeric of the HLA class II genes. 22 We have had the opportunity to study a large Bedouin kindred with a remarkably high prevalence of islet autoimmunity and extensive variability in phenotypic expression, ranging from classical childhood-onset type 1 diabetes to latent autoimmune diabetes in adults 6, 23 and islet autoantibodies without clinical disease. Furthermore, the family is segregating an atypical DR3-DQ5 haplotype (DRB1*0301-DQA1*0102-DQB1*0502) in addition to multiple DR3-DQ2 haplotypes, the latter of which display remarkable diversity in microsatellite alleles within a few hundred kilobases of the class II genes. Based on extensive follow-up studies of the development and progression of islet autoimmunity, we conclude that DR3 and DQ2 influence disease susceptibility at different stages in the development of islet autoimmunity, with DR3 contributing to the initial appearance of islet autoantibodies, and DQ2 contributing to early onset and severe clinical disease.
Results and discussion
The Bedouin kindred was identified in 1989 when the 6-month-old proband was diagnosed with type 1 diabetes at an Israeli clinic. The majority of living relatives reside in an isolated community within a small Israeli village. As of 1992, 13 living and 2 deceased relatives had developed autoimmune diabetes at ages ranging from 6 months to 45 years (median 20.0 years). Follow-up studies of islet autoantibodies and diabetes were carried out between 1992 and 2004, during which time 10 relatives were newly diagnosed with autoimmune diabetes at ages ranging from 2 to 36 years (median 11.5 years). As of 2004, the extended kindred consisted of 242 living and deceased relatives spanning seven generations and including at most 32 founders. One or more blood samples were collected from 182 relatives, including all diabetes-affected relatives and the majority of unaffected relatives living in the same community. Serum samples were measured by radioassay for autoantibodies to the insulin, GAD65, and ICA512 (IA-2) islet cell autoantigens as described. 24 HLA-DRB1, -DQA1 and -DQB1 exon 2 alleles were amplified using PCR and typed with sequence-specific oligonucleotide probes. 25, 26 Additionally, 157 samples were genotyped using the DeCode Genetics (Reykjavik, Iceland) multiplex set of 63 MHCspecific microsatellite markers spanning a 9.38 Mb and 5.75 cM region encompassing the extended MHC. All microsatellite genotyping was performed at DeCode Genetics with a genotyping call rate of 93.9%. The study was approved by the appropriate institutional review boards of the Israeli Health Care Authority and the University of Colorado Health Sciences Center, and informed consent was obtained from the participants.
Islet cell autoantibodies were detected in 12 initially asymptomatic relatives, three of whom (25%) progressed to diabetes at 2, 5 and 8 years after the first positive test. One of these, who was GAD65 autoantibody-positive at 24 years of age, was misclassified as type 2 diabetes at age 32, progressing to insulin-treated diabetes while remaining GAD65 autoantibody-positive at age 35. Of six other newly diagnosed relatives, three were autoantibody-positive when first tested at disease onset, two were negative for islet autoantibodies when last tested 1 year prior to disease onset and another relative was negative 2 and 4 years after disease onset. Overall, there was remarkable variation in the age of onset of diabetes among 25 total diabetes-affected relatives, ranging from 6 months to 48 years (median 18 years). There was also remarkable variation in the length of the preclinical period, with 9 autoantibody-positive relatives remaining diabetes-free after a median of 12 years after the first positive test (range 1-13 years).
HLA genotypes were available for 23 living affected relatives, including one deceased affected relative whose HLA haplotypes were inferred from the genotypes of his spouse and 12 offspring, 9 asymptomatic autoantibodypositive relatives and 146 unaffected relatives. We identified a total of 18 different class II haplotypes, including two DR3 haplotypes, one with DQ2 (DQA1*0501-DQB1*0201), which is also found in many other populations, and the other with DQ5 (DQA1*0102-DQB1*0502), which is absent or extremely rare in other populations. Based on the diversity of flanking microsatellite markers, 10 of the 18 class II haplotypes (including DR3-DQ5) traced to a single founder, and the remaining 8 (including DR3-DQ2) traced to multiple founders. A total of 40 founder haplotypes were recovered, representing the majority of a maximum of 53 haplotypes segregating in the kindred based on reported pedigree relationships and allowing for the loss of haplotypes from founders with a single offspring. DR3-DQ2 was present on five different founder haplotypes, all of which showed significant diversity in microsatellite alleles (450% pairwise differences in alleles) mapping within 0.5 cM on either side of the three class II genes. Similar to other Arab populations, 27 the three most common class II haplotypes were DR3-DQ2 (12.5%), DR5 (DRB1*11-DQA1*0501-DQB1*0301) (15%) and DR7 (DRB1*0701-DQA1*0201-DQB1*0201) (20%).
All of 24 relatives with diabetes and 7 of the 9 relatives with islet autoantibodies without diabetes inherited one or both DR3 haplotypes compared to 93 of 146 relatives without islet autoimmunity (97 vs 63.7%, Po4.3 Â 10 À5 ), consistent with the well-known association between autoimmune diabetes and DR3 in other populations. Remarkably, 23 of 24 diabetes-affected relatives inherited DR3-DQ2 compared with 2 of 9 asymptomatic autoantibody-positive relatives (Po6.4 Â 10
À5
, Fisher exact test); conversely, 2 of 24 diabetes-affected relatives inherited DR3-DQ5 compared with 7 of 9 asymptomatic autoantibody-positive relatives (Po2.7 Â 10
À4
, Fisher exact test). As shown in Table 1 , analyses using a computer simulation that accounts for the complex pedigree structure and the relative frequencies of founder haplotypes confirmed that DR3-DQ2 is preferentially transmitted to offspring with diabetes (P ¼ 0.0003) but not to autoantibody-positive offspring without diabetes (P ¼ 0.4727); and conversely, DR3-DQ5 is preferentially transmitted to autoantibody-positive offspring without diabetes (P ¼ 0.003) but not to offspring with diabetes (P ¼ 0.1867).
We used backward conditional logistic regression to distinguish primary and secondary effects of DR3 and DQ2 on the activation and progression of islet autoimmunity. As shown in Table 2 , the activation phenotype is best explained by a model that includes DR3 without DQ2 (AIC ¼ 153.91), whereas a model that includes DQ2 without DR3 is rejected (P ¼ 0.0096). The progression phenotype, on the other hand, is best explained by the full model that includes both DR3 and DQ2 (AIC ¼ 20.872). In this case, a model that includes DR3 without DQ2 is rejected convincingly (Po0.00001). A model that includes DQ2 without DR3 is also rejected, although the effect of DR3 is relatively modest (P ¼ 0.0464), and could reflect the complete (but imperfect) linkage disequilibrium of DQ2 with DR3. Altogether, the results indicate that both DR3 and DQ2 are involved in the development of islet autoimmunity, with DR3 influencing initial stages characterized by islet autoantibody positivity and DQ2 possibly in conjunction with DR3 influencing subsequent progression to clinical disease.
Interestingly, none of six relatives with DRB1*16-DQ5 developed islet autoantibodies or diabetes compared with 9 of 34 affected relatives with DR3-DQ5, which, although a statistically nonsignificant (P ¼ 0.31) difference, lends support to the importance of DR3 in the preclinical stage of islet autoimmunity. While other studies have shown that DRB1*16-DQ5 and DRB1*15-DQ5 are permissive for childhood diabetes among Sardinians 28 and Filipinos, 29 respectively, it is not known if this is an isolated effect of DQ5 or a genotypic effect that depends on the haplotype paired with DQ5, and in particular, on the presence of DR3-DQ2.
Quantitative analyses of the effects of DQ2 on the age of onset of overt diabetes were carried out using log-rank tests to compare diabetes-free survival curves between genotypes differing only by the presence of DQ2 or DQ5. As shown in Figure 1 , DQ2 is associated with earlier onset diabetes (P ¼ 0.0256) after controlling for a DR3 allele paired with a DR7 haplotype (Figure 1b) . A similar trend is seen after controlling for a DR3 allele paired with a DR3-DQ2 haplotype (Figure 1a) , although the latter effect barely escapes the minimum criterion for statistical significance (P ¼ 0.0522). As shown in Figure 1c , diabetes-free survival curves differ significantly (P ¼ 0.002) when different haplotypes are paired with DR3-DQ2, a result driven primarily by a notable absence of the common DR5 haplotype among DR3-DQ2 relatives with islet autoimmunity with or without diabetes. Overall, the results confirm that DQ2, when combined with a limited set of permissive haplotypes, influences diabetes susceptibility by accelerating the progression of islet autoimmunity, often resulting in classical type 1 diabetes at a relatively young age.
Based on the diversity of microsatellite alleles on DR3-DQ2 founder haplotypes, our results most likely reflect the direct effects of DR3 and DQ2 rather than secondary effects of linkage disequilibrium with another causal variant(s). Figure 2 shows the microsatellite allele content of the three DR3-DQ2 haplotypes found in affected relatives. Only the closest microsatellite marker allele on the telomeric side of DRB1 was shared by all three haplotypes, thus localizing the primary disease variant(s) to a 348.8 kb interval that includes DRB1, DQA1 and DQB1. We also examined the origin of the DR3-DQ5 haplotype by aligning the haplotype against the DR3-DQ2 haplotypes and a DR2-DQ5 haplotype (DRB1*16-DQA1*0102-DQB1*0502), the only other founder haplotype carrying the DQ5 allele. DR3-DQ5 shared a 5-locus microsatellite haplotype with a DR3-DQ2 haplotype (N ¼ 9) ). Separate analyses were carried out with each phenotype defined as a dependent variable and the number of DR3 alleles, the number of DQ2 haplotypes or both defined as independent variables. The relative effects of DR3 and DQ2 on each phenotype were evaluated using likelihood ratio tests to compare a full model that included both DR3 and DQ2 (row 1) to models that included one or the other but not both (rows 2 and 3). The model providing the best fit to the phenotype data was identified using the AIC. Statistical analyses were performed using SAS 9.1 (SAS Institute Inc, Cary, NC, USA). Results of computer simulations of the transmission of founder haplotypes through the kindred. Two phenotypes were examined:
(1) T1D ¼ relatives with autoimmune diabetes (N ¼ 24) and (2) Ab+ ¼ relatives with islet autoantibodies without autoimmune diabetes (N ¼ 9). Founder haplotypes were assigned randomly to founders based on their relative frequencies, and Mendelian segregation probabilities were used to transmit the haplotypes to descendents. The relative frequencies of different class II haplotypes in pedigree founders were estimated using microsatellite markers to distinguish founder haplotypes with identical class II alleles from haplotypes that were identical by descent from a recent common ancestor. Empirical significance levels for preferential transmission were calculated as the number of 30 000 replicates in which the number of affected relatives who inherited a given haplotype (either DR3-DQ2 or DR3-DQ5) was as extreme or more extreme than the observed number of affected relatives with that haplotype. Figure 2 ), extending 419.6 kb telomeric of DRB1 and a 3-locus haplotype with DR2-DQ5, extending 208.2 kb on the centromeric side of DQB1 (designated N in Figure 2) . Thus, the data are consistent with recombination occurring between the DRB1 and DQA1 loci involving a DR3-DQ2 haplotype (haplotypes T or I in Figure 2 ) and the DR2-DQ5 haplotype, most likely occurring in a distant generation, although we cannot rule out a more recent event involving one or more unrecovered founder haplotypes.
Differential effects of DR and DQ
Altogether, the current results integrate well with evidence and speculations pointing to a broad and nonspecific immunopathogenic effect of DR3, 20, 30, 31 an association of DR3 with islet autoantibody-positivity with or without progression to diabetes, 32 independent associations of DR4 and DQ8 with type 1 diabetes 33 and a delayed effect of DQ that may accelerate or hinder the progression of b-cell destruction and dysfunction. 12, [34] [35] [36] We previously reported significant clustering and coclustering of islet and celiac autoimmunity in the kindred, explained in part by a common association with DR3-DQ2, which was present in all of 16 relatives with celiac autoimmunity. 37 Interestingly, the frequency of DR3-DQ5 was higher among relatives with celiac autoimmunity compared to unaffected relatives with DR3-DQ2 (0.19 vs 0.05 among DR3-DQ2 relatives with and without celiac autoimmunity), although the difference was not statistically significant (Po0.10) and there was no difference in the distribution of class II haplotypes between relatives with celiac disease and relatives with celiac-related autoantibodies without celiac disease. Nevertheless, the results are consistent with the hypothesis that DR3 is primarily responsible for the association of celiac and islet autoimmunity in the kindred whereas DQ2 determines more specific aspects of phenotypic expression including the manifestation, age of onset and severity of autoimmune disease.
The dual role of DR and DQ in childhood-onset type 1 diabetes has been confirmed in many studies showing that the risk associated with DQ8 depends on the presence of a permissive DR4 subtype such as DRB1*0401 or DRB1*0405, and conversely, the risk associated with permissive DR4 subtypes depends on the presence of DQ8. Interestingly, most studies report a Figure 1 The effect of DQ2 on the rate of progression to clinical diabetes measured as the fraction of relatives surviving to a given age without diabetes, and showing P-values from log-rank tests of genotypic differences. (a) Effect of substituting DQ2 for DQ5 on a DR3 haplotype paired with DR3-DQ2; (b) effect of substituting DQ2 for DQ5 on a DR3 haplotype paired with DR7; and (c) differences in the effects of DR3-DQ2 depending on the haplotype paired with this haplotype. Legend key: 3 ¼ DR3-DQ2; 3 0 ¼ DR3-DQ5; 7 ¼ DR7; 4 ¼ DR4-DQ8; X ¼ any haplotype other than DR3, DR3 0 , DR7 or DR4-DQ8. Kaplan-Meier survival analyses were done using SAS version 9.1. Figure 2 Map and microsatellite allele content of a 500 kb region surrounding the class II HLA-DRB1, -DQA1 and -DQB1 genes on chromosome 6p21, indicating the smallest region of overlap (348.8 kb) among three diabetogenic founder DR3-DQ2 haplotypes (haplotypes B, T and I), the maximum length of the region shared on the telomeric side of DRB1 by the unique DR3-DQ5 haplotype (haplotype A) and any diabetogenic DR3-DQ2 haplotype (haplotype I, maximum of 419.6 kb shared with haplotype A), and the maximum length of the region shared on either side of the class II genes by DR3-DQ5 (haplotype A) and DRB1*16-DQ5 (haplotype N, maximum of 419.6 kb on the telomeric side of the class II genes shared with haplotype A; maximum of 208.2 kb on the centromeric side of class II shared with haplotype A).
Differential effects of DR and DQ E Eller et al stronger association with DQA1 and DQB1 nucleotides, alleles, haplotypes and genotypes than with DRB1 alleles and genotypes. 38 In light of our results, this could reflect a confounding of genetic influences on the activation and progression of islet autoimmunity in samples restricted to the most severe subset of patients with autoimmune diabetes.
The present study is unique in several important respects. First, the finding of an atypical DR3 haplotype in an extended family with a high prevalence of celiac and islet autoimmunity allowed us to isolate the effects DR3 and DQ2 on the development of islet autoimmunity. Our results showing the effects of both DR3 and DQ2 agree well with other studies, which, although limited by the near perfect linkage disequilibrium between DR3 and DQ2, have consistently ruled out an effect of either DQA1*0501 or DQB1*0201 in the absence of DR3. 39, 40 Second, the diversity of DR3-DQ2 founder haplotypes in relatives with islet autoimmunity made it possible to localize the effect to a B350 kb interval containing the three class II loci. Finally, the relatively small number of affected and unaffected relatives made it feasible to characterize different stages in the development of autoimmune diabetes and celiac disease, which when combined with prospective follow-up studies revealed remarkable variation in the severity, age of onset and expression of autoimmunity within a genetically and environmentally homogeneous extended kindred. In addition to demonstrating the combined effects of DR3 and DQ2 in the development of autoimmune diabetes, our results support a broad and relatively nonspecific role for DR3 in the initial autoimmune response while DQ2 is associated with earlier onset and possibly broader and more severe phenotypic expression. It will be important to determine if analogous effects apply to predisposing DR4 subtypes and DQ8, but this will require similar studies of multiple autoimmunity phenotypes in unbiased samples. Overall, our results strengthen arguments in support of genetic studies with a focus on effect sizes in relatively small samples of phenotypically well-characterized patients, 41 while providing empirical support for the detailed and prospective characterization of multiple preclinical and clinical autoimmunity phenotypes in a large population-based sample of birth cohorts. 42, 43 
